Identification of Patients Who Could Benefit from Bedaquiline or Delamanid: a Multisite MDR-TB Cohort Study

Hdl Handle:
http://hdl.handle.net/10144/600298
Title:
Identification of Patients Who Could Benefit from Bedaquiline or Delamanid: a Multisite MDR-TB Cohort Study
Authors:
Bonnet, M; Bastard, M; du Cros, P; Khamraev, A; Kimenye, K; Khurkhumal, S; Hayrapetyan, A; Themba, D; Telnov, A; Sanchez-Padilla, E; Hewison, C; Varaine, F
Journal:
The International Journal of Tuberculosis and Lung Disease
Abstract:
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome.
Publisher:
International Union Against TB and Lung Disease
Issue Date:
1-Feb-2016
URI:
http://hdl.handle.net/10144/600298
DOI:
10.5588/ijtld.15.0962
PubMed ID:
26792469
Type:
Article
Language:
en
ISSN:
1815-7920
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorBonnet, Men
dc.contributor.authorBastard, Men
dc.contributor.authordu Cros, Pen
dc.contributor.authorKhamraev, Aen
dc.contributor.authorKimenye, Ken
dc.contributor.authorKhurkhumal, Sen
dc.contributor.authorHayrapetyan, Aen
dc.contributor.authorThemba, Den
dc.contributor.authorTelnov, Aen
dc.contributor.authorSanchez-Padilla, Een
dc.contributor.authorHewison, Cen
dc.contributor.authorVaraine, Fen
dc.date.accessioned2016-02-28T14:11:04Zen
dc.date.available2016-02-28T14:11:04Zen
dc.date.issued2016-02-01en
dc.identifier.citationIdentification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. 2016, 20 (2):177-86 Int. J. Tuberc. Lung Dis.en
dc.identifier.issn1815-7920en
dc.identifier.pmid26792469en
dc.identifier.doi10.5588/ijtld.15.0962en
dc.identifier.urihttp://hdl.handle.net/10144/600298en
dc.description.abstractThe World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome.en
dc.language.isoenen
dc.publisherInternational Union Against TB and Lung Diseaseen
dc.rightsArchived with thanks to The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Diseaseen
dc.subjectTBen
dc.titleIdentification of Patients Who Could Benefit from Bedaquiline or Delamanid: a Multisite MDR-TB Cohort Studyen
dc.typeArticleen
dc.identifier.journalThe International Journal of Tuberculosis and Lung Diseaseen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.